Cargando…
[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results
BACKGROUND: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722628/ https://www.ncbi.nlm.nih.gov/pubmed/26796633 http://dx.doi.org/10.1186/s13014-016-0586-x |
_version_ | 1782411389617307648 |
---|---|
author | Pasqualetti, Francesco Panichi, Marco Sainato, Aldo Matteucci, Fabrizio Galli, Luca Cocuzza, Paola Ferrazza, Patrizia Coraggio, Gabriele Pasqualetti, Giuseppe Derosa, Lisa Sollini, Martina Mannelli, Lorenzo Ortori, Simona Monzani, Fabio Ricci, Sergio Greco, Carlo Fabrini, Maria Grazia Erba, Paola Anna |
author_facet | Pasqualetti, Francesco Panichi, Marco Sainato, Aldo Matteucci, Fabrizio Galli, Luca Cocuzza, Paola Ferrazza, Patrizia Coraggio, Gabriele Pasqualetti, Giuseppe Derosa, Lisa Sollini, Martina Mannelli, Lorenzo Ortori, Simona Monzani, Fabio Ricci, Sergio Greco, Carlo Fabrini, Maria Grazia Erba, Paola Anna |
author_sort | Pasqualetti, Francesco |
collection | PubMed |
description | BACKGROUND: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [(18)F]Choline ([(18)F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). METHODS: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [(18)F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [(18)F]FMCHPET/CT. RESULTS: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3–40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20–62.14 months). No grade 3 or 4 toxicity was recorded. CONCLUSIONS: Repeated salvage [(18)F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa. |
format | Online Article Text |
id | pubmed-4722628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47226282016-01-23 [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results Pasqualetti, Francesco Panichi, Marco Sainato, Aldo Matteucci, Fabrizio Galli, Luca Cocuzza, Paola Ferrazza, Patrizia Coraggio, Gabriele Pasqualetti, Giuseppe Derosa, Lisa Sollini, Martina Mannelli, Lorenzo Ortori, Simona Monzani, Fabio Ricci, Sergio Greco, Carlo Fabrini, Maria Grazia Erba, Paola Anna Radiat Oncol Research BACKGROUND: A new entity of patients with recurrent prostate cancer limited to a small number of active metastatic lesions is having growing interest: the oligometastatic patients. Patients with oligometastatic disease could eventually be managed by treating all the active lesions with local therapy, i.e. either surgery or ablative stereotactic body radiotherapy. This study aims to assess the impact of [(18)F]Choline ([(18)F]FMCH) PET/CT and the use stereotactic body radiotherapy (SBRT) in patients (pts) with oligometastatic prostate cancer (PCa). METHODS: Twenty-nine pts with oligometastatic PCa (≤3 synchronous active lesions detected with [(18)F]FMCHPET/CT) were treated with repeated salvage SBRT until disease progression (development of > three active synchronous metastases). Primary endpoint was systemic therapy-free survival measured from the baseline [(18)F]FMCHPET/CT. RESULTS: A total of 45 lesions were treated with SBRT. After a median follow-up of 11.5 months (range 3–40 months), 20 pts were still in the study and did not receive any systemic therapy. Nine pts started systemic therapy, and the median time of the primary endpoint was 39.7 months (CI 12.20–62.14 months). No grade 3 or 4 toxicity was recorded. CONCLUSIONS: Repeated salvage [(18)F]FMCHPET/CT-guided SBRT is well tolerated and could defer the beginning of systemic therapy in selected patients with oligometastatic PCa. BioMed Central 2016-01-22 /pmc/articles/PMC4722628/ /pubmed/26796633 http://dx.doi.org/10.1186/s13014-016-0586-x Text en © Pasqualetti et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Pasqualetti, Francesco Panichi, Marco Sainato, Aldo Matteucci, Fabrizio Galli, Luca Cocuzza, Paola Ferrazza, Patrizia Coraggio, Gabriele Pasqualetti, Giuseppe Derosa, Lisa Sollini, Martina Mannelli, Lorenzo Ortori, Simona Monzani, Fabio Ricci, Sergio Greco, Carlo Fabrini, Maria Grazia Erba, Paola Anna [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
title | [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
title_full | [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
title_fullStr | [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
title_full_unstemmed | [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
title_short | [(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
title_sort | [(18)f]choline pet/ct and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary results |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722628/ https://www.ncbi.nlm.nih.gov/pubmed/26796633 http://dx.doi.org/10.1186/s13014-016-0586-x |
work_keys_str_mv | AT pasqualettifrancesco 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT panichimarco 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT sainatoaldo 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT matteuccifabrizio 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT galliluca 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT cocuzzapaola 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT ferrazzapatrizia 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT coraggiogabriele 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT pasqualettigiuseppe 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT derosalisa 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT sollinimartina 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT mannellilorenzo 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT ortorisimona 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT monzanifabio 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT riccisergio 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT grecocarlo 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT fabrinimariagrazia 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults AT erbapaolaanna 18fcholinepetctandstereotacticbodyradiotherapyontreatmentdecisionmakingofoligometastaticprostatecancerpatientspreliminaryresults |